Track record · closed signal

Eli Lilly and Company (LLY) — closed signal from March 3, 2026

Near target Published before the outcome was known, scored automatically when the window closed on June 1, 2026 — +7.2% at the close.

Predicted vs. what happened

LLY price · publication thesis → realized outcomesplit-adjusted

$980.00 – $1,025.00Entry zone — fair-value band

$1,009.97Published — price the day we called it

$1,171.57Target — the price the thesis aimed for

$1,149.10Peak — highest point inside the window, not a realized return

$1,082.20Window close — end-of-window price, context only

What happened

Near target

Came within reach: 86% of the predicted growth at its peak, just short of the target.

At window close

+7.2%

realized, from the publication price to the last close inside the window

Peak gain

+13.8%

peak, from the publication price — not a realized return

S&P 500, same window

+11.8%

SPY over the identical days, dividend-adjusted

Window close

$1,082.20

last close inside the window, ended June 1, 2026

Peak price

$1,149.10

peak on May 28, 2026 — not a realized return

Days to target

—

The thesis — published March 3, 2026

Predicted growth

+16%

over the measurement window

Target price

$1,171.57

the price the thesis aimed for

Entry zone

$980.00 – $1,025.00

the fair-value band we waited for

Price at publication

$1,009.97

published March 3, 2026

Confidence

80%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

The stock pulled back after a period of strong buying, so it looks set up for a bounce back toward prior price levels if it calms down. Recent news suggests the drop may have gone too far and demand for GLP-1 products should keep long-term interest steady. If the price stabilizes over the next 0-3 months, a measured rebound is plausible while keeping downside risk limited.

Primary drivers

Analyst notes that the recent dip looks like a buying chance
Strong, ongoing demand for GLP-1 related products
Price being oversold can lead to a rebound
Big company size makes staged buying easier

How it played out

LLY: rebound came close, but the target was not reached

Lyra published LLY at 1009.97 on 2026-03-03 with expected growth of 16%. The thesis pointed to a pullback after strong buying, a possible bounce back toward prior price levels, steady demand for GLP-1 products, oversold conditions, and the company's size as support for staged buying.

Inside the window, LLY rose to 1149.10 on 2026-05-28, a 13.8% peak gain. That stayed below the 1171.57 target. The stock ended the window at 1082.20 on 2026-06-01. The thesis partly played out: the rebound happened, but it never got there.

What happened during the window

On 2026-04-01, The Guardian reported that U.S. regulators approved Lilly's oral GLP-1 weight-loss pill. On 2026-04-30, MarketWatch reported Lilly's first-quarter 2026 GLP-1 sales and its raised 2026 revenue forecast. These were reported events during the window, not stated causes of the stock move.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All LLY signals